Model Medicines presented an update on its lead candidate, MDL-001, at the Biocom Global Partnering Conference in California. MDL-001 is being positioned as a potential broad-spectrum oral antiviral, with reported preclinical activity across respiratory, hepatic, and gastrointestinal viral families. Comparative analyses indicating equivalence to established direct-acting antivirals such as remdesivir in SARS-CoV-2 animal models and sofosbuvir in hepatitis C virus (HCV) animal models, alongside reported superiority to nirmatrelvir in SARS-CoV-2 animal models, support its early differentiation within the antiviral landscape.
Significant advances have been made in the management of viral hepatitis in recent years. The introduction of highly effective direct-acting antivirals has transformed the HCV treatment landscape, enabling cure rates exceeding 95% in most patient populations and shifting clinical focus toward diagnosis and treatment access. Progress is also emerging in chronic hepatitis B (HBV) infection, where although current therapies remain largely suppressive rather than curative, the pipeline is increasingly focused on achieving a functional cure. GlobalData analysis identifies five functional cure components currently in late-stage development, which together are projected to generate over $2.1bn in revenue across seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan) by 2034. Despite these advances, unmet needs remain in hepatitis management, particularly in patients with viral co-infections, where treatment strategies can become more complex. For example, in HCV/HBV co-infected patients, direct-acting antivirals used to treat HCV infection carry the risk of HBV reactivation. Additionally, hepatitis D virus (HDV), an infection that only occurs in those already infected with HBV, continues to present limited treatment options and poorer clinical outcomes. With activity across HCV, HBV, and HDV, MDL-001 could be well-positioned to address such treatment gaps in the management of co-infected patients.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
At the same time, reported activity across RSV, influenza, and SARS-CoV-2 broadens MDL-001’s potential relevance beyond chronic liver infections. In respiratory settings, a broad-spectrum antiviral may offer value in early empiric treatment scenarios, particularly when the causative pathogen has not yet been identified or when viral co-infections occur. Such flexibility could be advantageous during seasonal surges or emerging outbreaks.
More broadly, development of an oral agent with activity spanning multiple viral families represents a departure from the traditionally pathogen-specific antiviral model. If clinical validation is achieved, this approach may be viewed favourably in the context of pandemic preparedness planning and potential government stockpiling strategies, where therapeutic versatility and ease of deployment are critical considerations. As the program remains in preclinical development, forthcoming clinical data will determine its ultimate positioning within the infectious disease landscape.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
